Clinical Presentation and Outcomes of Hospitalized Patients with Chronic Kidney Disease and COVID-19 Variant Omicron
DOI: https://doi.org/10.2147/tcrm.s458859
2024-05-19
Therapeutics and Clinical Risk Management
Abstract:Xiaolong Wang, Xueying Cao, Shuang Liang, Guangyan Cai Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Diseases, Beijing, People's Republic of China Correspondence: Xueying Cao, Department of Nephrology, Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, 28 Fuxing Road, Beijing, 100853, People's Republic of China, Tel +86 159 1049 3688, Email ; Purpose: To investigate the clinical characteristics of hospitalized patients with chronic kidney disease (CKD) and novel coronavirus (SARS-CoV-2) infection and identify potential risk factors that contribute to mortality. Patients and Methods: This is a retrospective study, conducted on patients with CKD who were admitted to the First Medical Center of the People's Liberation Army General Hospital between December 1, 2022, and February 28, 2023. All patients were also infected with SARS-CoV-2. We analyzed the clinical characteristics of patients, and the patients were categorized into a survival group and a death group whose characteristics were compared. Cox regression analysis was used to identify risk factors that affected patient prognosis. Results: A total of 406 patients were enrolled in this study, including 298 males (73.4%). The average age was 80.5 (67.0, 88.0) years, and the patients had an average estimated glomerular filtration rate (eGFR) of 50.3 (25.0– 79.0) mL/min/1.73m2. A total of 158 individuals died during hospitalization, resulting in a mortality rate of 38.9%. Renal function was worse in the death group than in the survival group (P < 0.001). Patients in the death group had more severe COVID-19 disease and higher CKD staging than those in the survival group (all P values < 0.001). Multivariate Cox regression analysis identified several risk factors that affected patient mortality, including being male, a higher resting heart rate (RHR) upon admission, dyspnea, a low lymphocyte count (Lym), a high international standardized ratio (INR), a high Acute Physiology and Chronic Health Evaluation II (APACHE II) score, heart failure, and the need for mechanical ventilation during the disease. Conclusion: Hospitalized patients with CKD who were infected with SARS-CoV-2 (38.9%) had a relatively high mortality rate (38.9%). Furthermore, a marked correlation was observed between a reduced eGFR and an increased risk of mortality. Keywords: SARS-CoV-2, estimated glomerular filtration rate, respiratory failure, mortality rate Coronavirus disease-19 (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus that set off a global pandemic with significant morbidity and mortality. COVID-19 patients with multiple co-morbidities, including chronic kidney disease (CKD), have a worse prognosis. 1 The worldwide prevalence of CKD is estimated to be 9–12% 2 and the condition is linked to a higher risk of hospitalization and outpatient pneumonia. 3 Patients with CKD have an approximately 10 times higher risk of mortality from pulmonary infections than the general population. 4 CKD is a significant risk factor for severe COVID-19 5 and is one of the most reliable predictors of prognosis among COVID-19 patients with severe and critical disease. 6 In a prospective cohort study 6 of 701 hospitalized patients with COVID-19, those with comorbid CKD had a two- to four-fold higher risk of death. A significant correlation between declining renal function and COVID-19-related mortality has also been demonstrated. 7 Specifically, patients with severe renal impairment (eGFR <30 mL/min/1.73 m 2 ; HR = 2.5) have a higher risk of death from COVID-19 than other high-risk populations, including individuals with obesity, neoplasia, chronic heart disease, and lung disease. Thus, it is critical to accurately characterize the prognosis and clinical progression of CKD patients with COVID-19. However, most studies on COVID-19 and CKD assessed patients infected with the Alpha or Delta strains of SARS-CoV-2. Since the Omicron variant did not become prevalent until after November 9, 2021, few studies have specifically examined the association between SARS-CoV-2 Omicron infection and CKD. Understanding the severity of COVID-19 disease in CKD patients studies is particularly important in China, which has been experiencing a nationwide epidemic since December 1, 2022. Thus, the current study focused on patients hospitalized in China with severe COVID-19 and CKD. Their clinical characteristics wer -Abstract Truncated-
health care sciences & services